SCHEDULE 13D/A: EcoR1 Capital Significantly Increases Stake in Galapagos NV to 11.84% with Over $371 Million Investment

Investment firm EcoR1 Capital, LLC and its affiliated funds have significantly increased their beneficial ownership in Galapagos NV to 11.84% of outstanding shares through recent open market purchases totaling over $371 million.

Summary

• EcoR1 Capital, LLC and its affiliates, including EcoR1 Capital Fund Qualified, L.P. and EcoR1 Capital Fund, L.P., now beneficially own an aggregate of 7,803,202 shares of Galapagos NV.
• This ownership represents approximately 11.84% of Galapagos NV's outstanding shares, based on 65,897,071 ordinary shares outstanding as of December 31, 2024, as reported in the Issuer's Form 20-F.
• The aggregate purchase price for these shares was $371,881,584.76, which includes fees and expenses but excludes fees related to the conversion of American Depositary Shares (ADSs) to Ordinary Shares.
• An additional $293,693.40 was paid in fees to Citibank, N.A. for the surrender of ADSs and withdrawal of ordinary shares.
• The funds used for these purchases and the ADS conversion were derived from the capital of EcoR1 Capital's affiliated funds.
• Recent transactions by EcoR1 Capital Fund, L.P. and EcoR1 Capital Fund Qualified, L.P. include multiple open market purchases of ADSs on NASDAQ and Ordinary Shares on Euronext between May 13, 2025, and May 16, 2025.
• ADS purchase prices ranged from $26.2791 to $27.5602 per share, while Ordinary Share purchases were at 23.0273 per share.

Sentiment

Score: 8

Explanation: The substantial increase in beneficial ownership by EcoR1 Capital, LLC, reaching 11.84% of outstanding shares through over $371 million in purchases, indicates strong investor confidence and a positive outlook from a major institutional player.

Positives

• Significant increase in institutional ownership by EcoR1 Capital, LLC and its affiliated funds, indicating strong investor confidence in Galapagos NV.
• The aggregate investment of over $371 million demonstrates a substantial financial commitment to the company.
• The conversion of ADSs to Ordinary Shares suggests a strategic, potentially long-term holding by the investor rather than short-term trading.

Future Outlook

The filing itself does not contain explicit forward-looking statements or guidance from Galapagos NV. However, the significant increase in beneficial ownership by EcoR1 Capital, LLC implies a positive long-term outlook from the investor's perspective on Galapagos NV's future prospects and value.

Industry Context

This filing indicates a significant investment by a specialized capital fund, EcoR1 Capital, in Galapagos NV, a company whose securities are traded on NASDAQ and Euronext. While the filing doesn't detail Galapagos NV's specific business, the nature of the securities (Ordinary Shares, ADSs) and the investor (EcoR1 Capital, often focused on biotech/healthcare) suggests it operates within the biotechnology or pharmaceutical sector. Such substantial institutional investments can signal confidence in a company's pipeline, market position, or strategic direction within its industry.

Comparison to Industry Standards

• This document is an ownership disclosure (Schedule 13D/A) and does not provide financial results or operational metrics of Galapagos NV that would allow for a direct comparison to industry standards, comparable companies, or projects. The focus is solely on the beneficial ownership stake of EcoR1 Capital.

Stakeholder Impact

• Shareholders: Existing shareholders may view the increased institutional ownership as a positive signal, potentially leading to increased investor confidence and share price stability or appreciation.
• Company Management: The significant stake by EcoR1 Capital could imply increased scrutiny or engagement from a major shareholder, potentially influencing strategic decisions.

Key Dates

Keywords

Galapagos NV, EcoR1 Capital, Schedule 13D/A, beneficial ownership, institutional investment, ordinary shares, American Depositary Shares, NASDAQ, Euronext, biotechnology, pharmaceutical, investment firm